» Articles » PMID: 25047574

Effect of Probiotics on Blood Pressure: a Systematic Review and Meta-analysis of Randomized, Controlled Trials

Overview
Journal Hypertension
Date 2014 Jul 23
PMID 25047574
Citations 191
Authors
Affiliations
Soon will be listed here.
Abstract

Previous human clinical trials have shown that probiotic consumption may improve blood pressure (BP) control. The aim of the present systematic review was to clarify the effects of probiotics on BP using a meta-analysis of randomized, controlled trials. PubMed, Scopus, Cochrane Library (Central), Physiotherapy Evidence Database, and Clinicaltrial.gov databases were searched until January 2014 to identify eligible articles. Meta-analysis using a random-effects model was chosen to analyze the impact of combined trials. Nine trials were included. Probiotic consumption significantly changed systolic BP by -3.56 mm Hg (95% confidence interval, -6.46 to -0.66) and diastolic BP by -2.38 mm Hg (95% confidence interval, -2.38 to -0.93) compared with control groups. A greater reduction was found with multiple as compared with single species of probiotics, for both systolic and diastolic BP. Subgroup analysis of trials with baseline BP ≥130/85 mm Hg compared with <130/85 mm Hg found a more significant improvement in diastolic BP. Duration of intervention <8 weeks did not result in a significant reduction in systolic or diastolic BP. Furthermore, subgroup analysis of trials with daily dose of probiotics <10(11) colony-forming units did not result in a significant meta-analysis effect. The present meta-analysis suggests that consuming probiotics may improve BP by a modest degree, with a potentially greater effect when baseline BP is elevated, multiple species of probiotics are consumed, the duration of intervention is ≥8 weeks, or daily consumption dose is ≥10(11) colony-forming units.

Citing Articles

Fecal microbiota transplantation for the treatment of intestinal and extra-intestinal diseases: Mechanism basis, clinical application, and potential prospect.

Yi D, Li T, Xiao Y, Zhang X, Hao Q, Zhang F Bioeng Transl Med. 2025; 10(2):e10728.

PMID: 40060755 PMC: 11883108. DOI: 10.1002/btm2.10728.


The Role of Gut Microbiota-Derived Trimethylamine N-Oxide in the Pathogenesis and Treatment of Mild Cognitive Impairment.

Xie H, Jiang J, Cao S, Xu X, Zhou J, Zhang R Int J Mol Sci. 2025; 26(3).

PMID: 39941141 PMC: 11818489. DOI: 10.3390/ijms26031373.


The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study.

Luangphiphat W, Prombutara P, Jamjuree P, Chantarangkul C, Vitheejongjaroen P, Muennarong C PLoS One. 2025; 20(1):e0317202.

PMID: 39792908 PMC: 11723615. DOI: 10.1371/journal.pone.0317202.


Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma.

Chen P, Yang C, Ren K, Xu M, Pan C, Ye X Front Immunol. 2024; 15:1504948.

PMID: 39650662 PMC: 11621041. DOI: 10.3389/fimmu.2024.1504948.


Next-Generation Probiotics and Chronic Diseases: A Review of Current Research and Future Directions.

Tiwari A, Krisnawati D, Susilowati E, Mutalik C, Kuo T J Agric Food Chem. 2024; 72(50):27679-27700.

PMID: 39588716 PMC: 11660543. DOI: 10.1021/acs.jafc.4c08702.